You just read:

Janssen's BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma

News provided by

The Janssen Pharmaceutical Companies of Johnson & Johnson

May 13, 2020, 17:10 ET